## Executive Summary – Q3 2021 HIT / Digital Health Update

Ч	Global M&A \$ value of \$1 T in Q3 2021 was \$\\$30\% on a QoQ basis, and \$\\$1.5x on a YoY basis. Deal count, on a QoQ basis was flat and \$\\$24\% on a YoY basis. U.S. M&A \$ value of \$678 Bil was up by \$\\$66\% QoQ and \$\\$3.4x on a YoY basis. Deal count YoY \$\\$49\%.
	Global Private Placements \$ value in Q3 2021 was $\downarrow$ 7% on a QoQ basis and $\uparrow$ 51% on a YoY basis. Deal count, on a QoQ and YoY basis were both up $\uparrow$ 7% and $\uparrow$ 33% respectively. U.S. Private Placements in Q3 was \$114 Bil. Deal count and \$ volume on a QoQ basis were flat and on a YoY basis deal count was $\uparrow$ 27% and \$ volume was $\uparrow$ 44%.
	U.S. Digital Health M&A total disclosed \$ volume in Q3 was ~\$10 Bil, ↓18% QoQ. Q3 deal count was 84 transactions, a slight decrease from a strong Q1 and Q2 2021 and ↑15% YoY.
	■ For the fist time in three years, the Spending and Revenue Analytics category was the most active in a quarter with 34 deals in Q3 2021. Patient Centric was the 2 <sup>nd</sup> most active with 24 deals but \$\dig 20\%\$ from Q2 deal count. Productivity Solutions had the most dramatic decline in deal count \$\dig 71\%\$ QoQ from 28 to 8 and \$\dig 69\%\$ YoY.
	U.S. Digital Health Private Placement transaction count slightly decreased to 252 deals in Q2, but 2021 had the strongest first three quarters of any year in the past 6 years. Disclosed dollar investments in NHA's defined N. American Digital Health sector \$5.3 Bil in Q3 2021 and was ↓27% from the record Q2 2021 level of \$7.3 Bil.
	■ The Patient Centric broad category continued to be the most active area for investments, registering 124 deals or 49% of total Q3 PP deals. Both the Provider and Patient Centric sectors enjoyed an ↑ in deal counts during Q3, 2021 while the Productivity Solutions, Clinical Data analytics, and Spending and Revenue Analytics all experienced a marginal ↓ in deals.
	Digital Health stocks entering the U.S. public markets in Q3 2021 took the form of three IPOs (Cue Health, Definitive Healthcare, and Thorn HealthTech), which began trading in mid-September. As of Sept, there are at least 3 SPAC deals in the pipeline for the Q4 2021 and H1 2022. Three new SPAC deals (Owlet, Sharecare, and Sema4) closed during Q3. All digital health SPAC deals in the past 3 quarters have experienced substantial declines in their stock prices, once floated.
	Novahill's Digital Health Public Comparable Index gained 11% compared to the S&P 500 Index's 27% gain over the latest 12-month period. Of note, the HIT stock index's outperformance was weighted by the exceptional results of 4 stocks (\\$101\% on average), while the other 22 stocks recorded an average \\$5\% gain over the LTM period (including 12 stocks with negative returns).